Skip to main content

How NZ differs from Australia and the EU

New Zealand's medical device regulatory system is intentionally lighter than those of its closest regulatory neighbours — Australia and the EU. Understanding the key differences avoids both under-compliance (assuming NZ is a free pass) and over-compliance (applying full EU MDR logic where it is not required).


Pre-market requirements

AspectNew ZealandAustralia (TGA)European Union
Pre-market approvalNot requiredRequired (ARTG)Required (CE marking)
Regulator review before supplyNoYes (for most classes)Via Notified Bodies
Formal conformity assessment routesNoneMultiple prescribed routesAnnex IX–XI routes
Third-party body involvementNone requiredFor higher-risk classesNotified Body for most devices

Practical implication: You can supply a device in NZ that has not received formal approval anywhere — as long as you can produce safety and performance evidence on request and you have a NZ Sponsor who has notified WAND.


Accepted overseas evidence

Medsafe has confirmed it accepts the following as evidence of conformity:

  • CE certificate from an EU Notified Body
  • TGA registration (ARTG listing) from Australia
  • FDA clearance or approval from the USA
  • Health Canada licence from Canada

No specific conformity assessment procedure is mandated for the NZ market — but the evidence must exist and must be held by the Sponsor or manufacturer.


Labelling

AspectNew ZealandAustraliaEU
Mandatory UDINoYes (staged rollout)Yes
Language requirementEnglishEnglishLanguage of country of supply
Reference standardGHTF/SG1/N43:2005TGA OrdersEU MDR Annex I
IFU required?Expected but not prescribedYesYes

IVDs — a significant difference

In New Zealand, IVDs are exempt from mandatory WAND notification under Schedule 1 of the Medicines (Database of Medical Devices) Regulations 2003. They can be notified voluntarily, and many sponsors do so. In contrast, Australia has a full IVD regulatory framework with mandatory ARTG listing, and the EU has the IVDR.


Post-market surveillance

AspectNew ZealandAustraliaEU
Mandatory PSURNoYes (for some classes)Yes
Periodic safety reportingNot prescribedYesYes
PMCF requiredNot prescribedFor some classesYes
PMS plan requiredNot prescribedYesYes

NZ's approach is lighter — sponsors must report adverse events and manage recalls, but there is no formal periodic reporting cycle comparable to EU PSURs.


Classification alignment

New Zealand's 22 classification rules are based on the GHTF (Global Harmonization Task Force) framework and closely aligned with both the EU Medical Devices Directive and Australian TGA classification rules. However:

  • The EU has since moved to the MDR (2017/745), which reclassified some device types upward
  • Australia has aligned its classification rules with the EU MDR
  • New Zealand has not yet adopted the MDR-era changes, so some discrepancies exist between NZ classes and EU/AU classes for certain device types

Always check classification under NZ Schedule 2 independently — do not assume your EU or AU class automatically carries over.


TTMRA — the special Australia–NZ arrangement

The Trans-Tasman Mutual Recognition Arrangement means that goods lawfully supplied in Australia can generally be supplied in NZ without separate NZ-specific regulatory approval. However, this does not eliminate WAND notification obligations for devices. See TTMRA and Australia for a full analysis.


Summary for manufacturers

Already have TGA, CE, or FDA clearance? You are well-positioned for the NZ market. Your existing evidence satisfies Medsafe's conformity evidence expectations. You still need a NZ Sponsor and must notify WAND within 30 days of supply commencing. Labelling may need minor adjustment.

No overseas regulatory clearance? You can still supply in NZ, but you must hold your own technical documentation, risk management records, and performance evidence — and a NZ Sponsor must be willing to take legal responsibility for the device.